CMOs will struggle to compete with large in-house capacity investments, according to Results Healthcare which predicts a decline in outsourced biomanufacturing.
Having a proactive approach to delivery technologies will give pharma firms a competitive edge against biosimilars and biobetters, according to device maker Bespak.
Vaccines being developed using Catalent's oral Zydis platform would increase compliance and cut costs but Big Pharma is slow to get on board, the firm says.
For the second straight year Charles River Laboratories has seen more of its revenue derived from biotech companies than Big Pharma, CEO James Foster told investors at two conferences on Tuesday and Wednesday.
Cubist will give Merck & Co leadership of the antibiotics sector according to one analyst who says renewed interest expressed by GSK, Roche and Sanofi has not produced any Ph III candidates.
Rottendorf is looking to break from being “the best kept secret in the CMO world” by targeting the thousands of virtual and SME pharma firms in the US, according to its CEO.
Investors only back drug innovators because they have to according to Index Venture Management's Kevin Johnson, who says less risky 'first to be second' firms are actually much more attractive.
Biopharma companies are not likely to outsource a larger chunk of their manufacturing than they have in the past 10 years, according to a new report from PharmSource.
Hardly anybody downloads Big Pharma apps according to a new report that suggests drugmakers seeking greater mHealth engagement should ditch the product-focused model and seek expert help.
Strategic relationships with contract manufacturers are becoming the standard, but big and small pharma demands differ considerably according to the two largest CDMOs, DPx and Catalent.
Efficient relationships with contract manufacturers are being held back by Big Pharma’s ‘intellectual arrogance’ and ill-defined operational teams, according to an ex-Director at GlaxoSmithKline.
CRO BioClinica will acquire Blueprint Clinical, which offers a cloud-based site scoring tool to help pharma address risk-based monitoring strategies for trials.
As big pharma and biotech companies increasingly take R&D centers offline, the companies are also looking to reduce the number of outsourcing partnerships, Jim Foster, CEO of Charles River Laboratories, said recently.
As pharma manufacturers look to cut costs and increase quality, over 70% of industry executives interviewed for a recent CPhI report say they are actively investing in manufacturing techniques and technologies to achieve these goals.
RNA interference (RNAi) developers that saw stock prices fall after Novartis pulled out of the market last week have reiterated their belief in the therapeutic and revenue potential of gene silencing drugs.
The climate for biomanufacturing has changed according to Pfizer, which has set out to win more contracting work for its hormone plant in Sweden and says it will even consider making large molecule drugs for Big Pharma rivals.
With small companies and biotechs increasingly discovering new products, there are big opportunities for contract development and manufacturing organisations (CDMO), says ex-GSK expert.
BioFocus has taken on Titian’s sample management software in a bid to pump more resources into “refreshing” its 900,000 strong high-throughput screening (HTS) compound portfolio.
Chiltern says that strategic partnering in the contract research sector enables CROs to plan for the longer term and is having a tangible impact on brining drugs to market.
IDT Biologika.says demand for vaccines in emerging markets is big chance for Big Pharma and hence a growing niche for contractors with the technical capabilities to carry out such work.
Just weeks after completing its billion dollar Wyeth takeover, US drug giant Pfizer has floated the idea of entering Japan’s $5.8bn (€3.9bn)-a-year generic drugs market in 2011 in a bid to further diversify its revenue streams.
As rumours of a failed Sanofi Aventis’ bid for a US rival circulate, F&S’ analysis of M&As is well timed, even if its conclusions will be difficult reading for a Big Pharma sector set on replenishing pipelines via big deals.
Although the downturn has slowed Big Pharma’s investment in China, the country’s wide ranging healthcare reforms and changing economic landscape still provide considerable opportunities says PricewaterhouseCoopers (PwC).
The annual sales growth of the top 20 pharma companies will fall below two per cent over the next five years, according to Datamonitor, and the stimulus packages are predicted to offer little direct aid.
Indian generics firm Piramal Healthcare says it "has no intention to dilute current ownership levels," but has not commented on rumours that it is in talks with French firm Sanofi Aventis.
Barack Obama’s support for R&D tax credits to boost innovation is designed to assuage Big Pharma’s fears about a ban on “authorised generics,” and new “comparative effectiveness" tests, according to Datamonitor’s Sandra Reynolds.
Contract research company Parexel saw its share rocket more than 30 per cent yesterday after it reported a hike in its second quarter revenues and despite a fallback in net profits.
Cost cutting has sustained pharma profits in the faltering global economy, however top executives are starting to realise that reducing R&D capacity may not have been the smartest move in an era of weak pipelines and impending patent expiry, according...
The contract manufacturing organisation (CMO) business model needs
to change if companies expect to remain competitive in this
evolving industry, which is tipped to see tough times ahead.
The often cited decline in R&D productivity and dwindling
innovation within the pharma industry is actually a thing of the
past, according to Wyeth's head of business development.
The current big pharma business model is not sustainable for the
future and will need to change, delegates heard at the recent
Financial Times (FT) global Pharmaceuticals and Biotechnology
Conference.
Britain's manufacturers of tailor-made non-licensed medicines are
working on establishing a unique supply agreement with major drug
firms that could serve as a model worldwide for the production of
drugs that meet the specialised...
Are big pharma companies uninterested in supporting novel
formulations, preferring to stick to low-risk drug delivery
systems, or are they resourceful innovators that bring new
technologies to the market? Two pharma grandees holding...
According to a new report, 2006 will be a crunch year for companies
that have expiring product patents looming. With generics
increasingly penetrating the market, this has thrown into doubt the
growth of this industry in the foreseeable...
Vioxx. Bextra. Zyprexa, Seroxat. At no period of time have so many
high-profile drugs come under the spotlight as drug companies face
legal action over drug safety. It's make or break time for the
pharmaceutical industry as drug...
A new report reveals that large pharmaceutical companies are
investing in less money and people in nanotech than other
industries, despite pressure to replace fading blockbuster drugs.
The top pharmaceutical companies are investing less money and
people in nanotechnology than other industries, despite pressure to
replace fading blockbuster drugs as fewer drugs come out of the
sector's R&D pipeline, according...
Drug companies are waking up to the notion that the environment a
researcher works in - whether in drug discovery or the quality
control lab - is a crucial factor in determining their productivity
and creativity. And they have started...
